Repository logo
 
Publication

Cetuximab plus platinum-based chemotherapy in head and neck Squamous Cell Carcinoma: a retrospective study in a single Comprehensive European Cancer Institution

dc.contributor.authorDe Mello, Ramon Andrade
dc.contributor.authorGerós, Sandra
dc.contributor.authorAlves, Marcos Pantarotto
dc.contributor.authorMoreira, Filipa
dc.contributor.authorAvezedo, Isabel
dc.contributor.authorDinis, Jose
dc.date.accessioned2018-12-07T14:53:04Z
dc.date.available2018-12-07T14:53:04Z
dc.date.issued2014-02
dc.description.abstractBackground: The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN). We investigated the efficacy and outcome of this protocol as a first-line treatment for patients with recurrent or metastatic disease. We evaluated overall-survival (OS), progression-free-survival (PFS), overall response rate (ORR) and the treatment toxicity profile in a retrospective cohort. Patients and Methods: This study enrolled 121 patients with untreated recurrent or metastatic SCCHN. The patients received PF+ cetuximab every 3 weeks for a maximum of 6 cycles. Patients with stable disease who received PF+ cetuximab continued to receive cetuximab until disease progressed or unacceptable toxic effects were experienced, whichever occurred first. Results: The median patient age was 53 (37-78) years. The patient cohort was 86.8% male. The addition of cetuximab to PF in the recurrent or metastatic setting provided an OS of 11 months (Confidential Interval, CI, 95%, 8.684-13.316) and PFS of 8 months (CI 95%, 6.051-9.949). The disease control rate was 48.9%, and the ORR was 23.91%. The most common grade 3 or 4 adverse events in the PF+ cetuximab regimen were febrile neutropenia (5.7%), skin rash (3.8%) and mucosistis (3.8%). Conclusions: The results of this study suggest that cetuximab plus platinum-fluorouracil chemotherapy is a good option for systemic treatment in advanced SSCHN patients. This regimen has a well-tolerated toxicity profile.
dc.description.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.1371/journal.pone.0086697
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/10400.1/11334
dc.language.isoeng
dc.peerreviewedyes
dc.publisherPublic Library of Science
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectClinical-practice guideline
dc.subjectPhase-Ii multicenter
dc.subject1St-line treatment
dc.subjectAntibody cetuximab
dc.subjectInduced nausea
dc.subjectRecurrent
dc.subjectAssociation
dc.subjectCisplatin
dc.subjectPolymorphism
dc.subjectTrial
dc.titleCetuximab plus platinum-based chemotherapy in head and neck Squamous Cell Carcinoma: a retrospective study in a single Comprehensive European Cancer Institution
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue2
oaire.citation.startPagee86697
oaire.citation.titlePLoS ONE
oaire.citation.volume9
person.familyNamede Mello
person.givenNameRamon Andrade
person.identifier.orcid0000-0002-9640-4573
rcaap.rightsopenAccess
rcaap.typearticle
relation.isAuthorOfPublication53ee625f-c5c3-468b-85bb-4cef5ad36928
relation.isAuthorOfPublication.latestForDiscovery53ee625f-c5c3-468b-85bb-4cef5ad36928

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
handle11334.pdf
Size:
313.46 KB
Format:
Adobe Portable Document Format